Comparative Effectiveness of the Dexamethasone Intravitreal Implant in Vitrectomized and Non-vitrectomized Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion

Shaikh, Adeel H.; Petersen, Michael R.; Sisk, Robert A.; Foster, Robert E.; Riemann, Christopher D.; Miller, Daniel M.

doi:10.3928/23258160-20121221-09

Cited by 23 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although similar results of comparison between non-PPV and PPV eyes have been reported in ME associated to CRVO, 18 this series is, to the best of our knowledge, one of first to report a comparative study between non-PPV and PPV eyes with uveitic ME treated with DEX-intravitreal implant. In our series, non-PPV eyes had greater risk of developing IOP increase and therefore, should have closer IOP monitoring after DEX-intravitreal implant injection.…”

Section: Discussionsupporting

confidence: 67%

“…Similar results have been reported in DEX-intravitreal implant for treatment of ME secondary to central retinal vein occlusion (CRVO). 18 Although the implant avoids systemic side effects, rise in IOP was the most common complication. Statistical analysis of IOP during all follow-up showed a higher IOP in non-PPV eyes compared with PPV eyes with statistically significant differences from third to 12th month.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis

Pelegrín

Maza

Molins

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose To compare dexamethasone (DEX) intravitreal implant effect in nonvitrectomized (non-PPV) vs vitrectomized (PPV) eyes with macular edema (ME) secondary to non-infectious uveitis. Methods Medical records of patients with uveitic ME treated with DEX-intravitreal implant were reviewed. Main outcome measures were changes in central retinal thickness (CRT), best corrected visual acuity (BCVA), intraocular pressure (IOP), vitreous haze and adverse events. Statistical analysis was performed by Longitudinal Linear model using the General Estimating Equation methodology. Results Forty-two eyes of 32 patients were included. Median follow-up time was 18 months (interquartile range (IQR): 12-24). Median CRT showed its maximum decrease at the first month in non-PPV and PPV eyes without statistically significant differences between both groups (P = NS). Median Snellen BCVA, converted to logarithm (LogMAR), showed its maximum improvement at third month in both groups without statistically significant differences between them (P = NS). Median IOP was higher in non-PPV eyes than in PPV eyes from third (P = 0.025) to 12th month (P = 0.013). Vitreous haze score improved in both groups since first month and showed no differences (P = 0.706). Reinjection was performed in 45.2% of eyes at a median time of 5 months IQR: (5-6). Ocular hypertension (47.6%) was the most common adverse event.Conclusions DEX-intravitreal implant for uveitic ME has similar long-term safety profile and good response measured in terms of CRT decrease, BCVA, and vitreous haze improvement in both groups. Non-PPV eyes following DEX-intravitreal implant showed higher IOP increase than PPV eyes, showing the need for close IOP monitoring.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis

Pelegrín

Maza

Molins

et al. 2015

Eye

View full text Add to dashboard Cite

show abstract

“…Rabbit‐studies have shown no difference in clearance rates of DII in vitrectomised and non‐vitrectomised eyes . The efficacy of DII has also been shown to be similar in vitrectomised and non‐vitrectomised eyes when used to treat macular oedema secondary to CRVO …”

Section: Steroid Preparations and Methods Of Local Administration To mentioning

confidence: 99%

Local delivery of corticosteroids in clinical ophthalmology: A review

Fung

Tran

Lim

et al. 2020

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Locally administered steroids have a long history in ophthalmology for the treatment of inflammatory conditions. Anterior segment conditions tend to be treated with topical steroids whilst posterior segment conditions generally require periocular, intravitreal or systemic administration for penetration. Over recent decades, the clinical applications of periocular steroid delivery have expanded to a wide range of conditions including macular oedema from retino-vascular conditions. Formulations have been developed with the aim to provide practical, targeted, longer-term and more efficacious therapy whilst minimizing side effects. Herein, we provide a comprehensive overview of the

show abstract

“…We hypothesized that the DEX implant would be a useful intraoperative adjunct to ERM peeling because its greater potency and prolonged exposure time compared to IVTA may be more effective at improving outcomes in the post-vitrectomy eye. [28][29][30] Prior reports of the use of DEX for ERM surgery have been limited to the management of refractory postoperative CME after PPV with ERM peeling. 31,32 In this study, we focused on the prophylactic placement of DEX to hasten and improve the therapeutic endpoint of normalized macular contour.…”

Section: Discussionmentioning

confidence: 99%

A Comparison of Intraoperative Dexamethasone Intravitreal Implant and Triamcinolone Acetonide Used During Vitrectomy and Epiretinal Membrane Peeling: A Case Control Study

Yonekawa¹,

Mammo²,

Thomas³

et al. 2016

Ophthalmic Surg Lasers Imaging Retina

View full text Add to dashboard Cite

show abstract

Comparative Effectiveness of the Dexamethasone Intravitreal Implant in Vitrectomized and Non-vitrectomized Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion

Abstract: This retrospective study shows similar CMT reductions with DEX implant treatment for CRVO-related macular edema in vitrectomized and non-vitrectomized eyes.

Cited by 23 publications

References 16 publications

Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis

Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis

Local delivery of corticosteroids in clinical ophthalmology: A review

A Comparison of Intraoperative Dexamethasone Intravitreal Implant and Triamcinolone Acetonide Used During Vitrectomy and Epiretinal Membrane Peeling: A Case Control Study

Contact Info

Product

Resources

About